Maxim Group Maintains Buy Rating on CERo Therapeutics (CERO)
In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) with a $3.00 price target.
Cero Therapeutics Holdings Inc. (CERO)
Market is closed
News
- Displaying 2
CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial
CERo Therapeutics Holdings, Inc.
Billionaire Hedge Funds
